Mazumder A, Gazit A, Levitzki A, Nicklaus M, Yung J, Kohlhagen G, Pommier Y
Laboratories of Molecular Pharmacology and Medicinal Chemistry, National Cancer Institute, Bethesda, Maryland 20892, USA.
Biochemistry. 1995 Nov 21;34(46):15111-22. doi: 10.1021/bi00046a018.
Efficient replication of HIV-1 requires establishment of the proviral state, i.e., the integration of a DNA copy of the viral genome, synthesized by reverse transcriptase, into a chromosome of the host cell. Integration is catalyzed by the viral integrase protein. We have previously reported that phenolic moieties in compounds such as napthoquinones, flavones, caffeic acid phenethyl ester (CAPE), and curcumin confer inhibitory activity against HIV-1 integrase. We have extended these findings by examining the effects of tryphostins, tyrosine kinase inhibitors. The catalytic activities of HIV-1 integrase and the formation of enzyme-DNA complexes using photocross-linking were examined. Both steps of the integration reaction, 3'-processing and strand transfer, were inhibited by tyrphostins at micromolar concentrations. The DNA binding activity of integrase was inhibited at higher concentrations of tryphostins. Disintegration, an apparent reversal of the strand transfer reaction, catalyzed by an integrase mutant lacking the N-terminal zinc finger and C-terminal DNA binding domains is also inhibited by tyrphostins, indicating that the binding site for these compounds resides in the central catalytic core of HIV-1 integrase. Binding of tyrphostins at or near the integrase catalytic site was also suggested by experiments showing a global inhibition of the choice of attacking nucleophile in the 3'-processing reaction. None of the tryphostins tested inhibited eukaryotic topoisomerase I, even at 100 microM, suggesting selectivity for integrase inhibition. Molecular-modeling studies have revealed that, after energy minimization, several tyrphostins may adopt folded conformations. The similarity of the tyrphostin family to other families of inhibitors is discussed. Tyrphostins may provide lead compounds for development of novel antiviral agents for the treatment of acquired immunodeficiency syndrome based upon inhibition of HIV-1 integrase.
HIV-1的有效复制需要建立前病毒状态,即由逆转录酶合成的病毒基因组DNA拷贝整合到宿主细胞的染色体中。整合由病毒整合酶蛋白催化。我们之前报道过,萘醌、黄酮、咖啡酸苯乙酯(CAPE)和姜黄素等化合物中的酚类部分具有抗HIV-1整合酶的抑制活性。我们通过研究酪氨酸激酶抑制剂曲古抑菌素的作用扩展了这些发现。使用光交联法检测了HIV-1整合酶的催化活性以及酶-DNA复合物的形成。曲古抑菌素在微摩尔浓度下抑制了整合反应的两个步骤,即3'-加工和链转移。在较高浓度的曲古抑菌素下,整合酶的DNA结合活性受到抑制。由缺乏N端锌指和C端DNA结合结构域的整合酶突变体催化的链转移反应的明显逆转——解体,也受到曲古抑菌素的抑制,这表明这些化合物的结合位点位于HIV-1整合酶的中央催化核心。显示对3'-加工反应中攻击亲核试剂选择的全面抑制的实验也表明曲古抑菌素在整合酶催化位点或其附近结合。所测试的曲古抑菌素均未抑制真核拓扑异构酶I,即使在100微摩尔浓度下也是如此,这表明对整合酶抑制具有选择性。分子建模研究表明,能量最小化后,几种曲古抑菌素可能会采取折叠构象。讨论了曲古抑菌素家族与其他抑制剂家族的相似性。基于对HIV-1整合酶的抑制作用,曲古抑菌素可能为开发用于治疗获得性免疫缺陷综合征的新型抗病毒药物提供先导化合物。